DRUG · Unmapped registry intervention
Dexelvucitabine
Find medicine records ·
Find other trials using this name
Clinical trial
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
NCT00300573
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedRandomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HIV Infectionsunresolved
Human Immunodeficiency Virusunresolved
Interventions
DexelvucitabineDRUG
Sponsors & collaborators
Incyte Corporationlead sponsor
Mapped research locations
New YorkNew York, United States1ChicagoIllinois, United States1DallasTexas, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1PortlandOregon, United States1Long BeachCalifornia, United States1Fort LauderdaleFlorida, United States1San JuanPuerto Rico1PlantationFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00300573 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.